GLP1 and SGLT2 Drugs Linked to Better Outcomes After Pacemaker Surgery

A retrospective analysis described in a PubMed listed study looked at whether two widely used diabetes drug classes relate to outcomes after pacemaker implantation in people with type 2 diabetes.

Researchers reviewed electronic health records for 3,609 patients with type 2 diabetes who received a pacemaker between 2016 and 2023. Patients were grouped by whether they were dispensed an SGLT2 inhibitor, a GLP1 receptor agonist, both, or neither, then followed for three years using a statistical weighting method to account for differences between groups.

Over the follow up period, 12.8 percent of patients died and 8.2 percent were hospitalized for heart failure. All three treated groups had lower mortality than those on neither drug class, with the largest reduction in patients using both medications together, a 59 percent lower relative risk. Combined therapy was also linked to a 65 percent lower relative risk of heart failure hospitalization, while single drug groups showed a trend in the same direction without reaching statistical significance.

This is observational data, not a randomized trial, so it shows association rather than proof that the drugs caused the improvement. The study authors themselves say these findings support testing cardiometabolic therapies after pacemaker implantation in controlled trials.

This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.